Mark Cuban Corrects Elizabeth Warren As She Slams JNJ, PFE For Higher Prices And Zero Taxes On Big Pharma: 'PBMs Corrupt Healthcare'
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 20 2025
0mins
Source: Benzinga
Healthcare Debate: A public dispute over U.S. drug pricing has emerged between billionaire Mark Cuban and Senator Elizabeth Warren, focusing on the role of Pharmacy Benefit Managers (PBMs) versus pharmaceutical companies in driving up costs.
Cuban's Critique: Cuban argues that PBMs are the main contributors to inflated drug prices due to their control over formularies and rebate negotiations, while Warren blames major pharmaceutical firms for exploiting tax loopholes to avoid paying federal taxes.
Analyst Views on PPH
Wall Street analysts forecast PPH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PPH is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 106.420
Low
Averages
High
Current: 106.420
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
